However, they arent a one-size-fits-all solution
The FDA intends to remove questionable active ingredients from the GLP-1 drug market
Finally, Jahraus emphasized that there is still much that scientists dont know about the long-term effects of these medications
If you are still routing patients to noncompliant compounded semaglutide after FDAs February 6, 2026 action, this is no longer a theoretical cleanup project
What UK law says The short version: none of these are licensed medicines in the UK, and supplying any of them for human use without a marketing authorisation is unlawful under the Human Medicines Regulations 2012
If you are experiencing unexpected symptoms on a GLP-1 medication, they may be worth discussing with a clinician, even if they are not on the standard side effect list